These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19409352)

  • 41. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
    Petkow-Dimitrow P
    Pol Arch Med Wewn; 2007 Apr; 117(4):44-50. PubMed ID: 17722475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 45. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 46. Lessons from ONTARGET.
    Berlaimont V; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Van Mieghem W; Vervaet P; Herman AG
    Acta Clin Belg; 2008; 63(3):142-51. PubMed ID: 18714845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telmisartan for the reduction of cardiovascular morbidity and mortality.
    Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 52. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
    Dans AL; Teo K; Gao P; Chen JH; Jae-Hyung K; Yusoff K; Chaithiraphan S; Zhu J; Lisheng L; Yusuf S;
    PLoS One; 2010 Dec; 5(12):e13694. PubMed ID: 21200437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2008 Apr; 63(4):213-9. PubMed ID: 18575077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.
    McFarlane SI
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1363-71. PubMed ID: 19900019
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pre-clinical and clinical experience of telmisartan in cardiac remodelling.
    Verdecchia P
    J Int Med Res; 2005; 33 Suppl 1():12A-20A. PubMed ID: 16222896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
    Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
    Wang JG; Pimenta E; Chwallek F
    Vasc Health Risk Manag; 2014; 10():189-200. PubMed ID: 24741317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.